{
    "clinical_study": {
        "@rank": "127707", 
        "brief_summary": {
            "textblock": "Multicenter prospective follow-up of a not controlled chronic hepatitis C genotypes 2/3\n      patients cohort with treatment indication with interferon \u03b1 2b and ribavirin for 24 weeks,\n      and the verification of sustained virological response at week 48.\n\n      The eligibility criteria and outcome measures followed the Clinical Protocol and Therapeutic\n      Guidelines for Chronic Viral Hepatitis C, published by the Ministry of Health:\n\n      http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf"
        }, 
        "brief_title": "Interferon \u03b1 2b Pharmacovigilance Study", 
        "completion_date": {
            "#text": "December 2012", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis C, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Genotype 2/3 Chronic Hepatitis C confirmed by biomolecular technology (RNAVHC);\n\n          -  Treatment naive;\n\n          -  Signing the Informed Consent Form;\n\n          -  Eligibility criteria and outcome measures followed the Clinical Protocol and\n             Therapeutic Guidelines for Chronic Viral Hepatitis C, published by the Ministry of\n             Health:\n             http://portal.saude.gov.br/portal/arquivos/pdf/pcdt_hepatite_c_2011_retificado.pdf\n\n        Exclusion Criteria:\n\n          -  Serious adverse events;\n\n          -  Intolerance to treatment;\n\n          -  Lost to follow up."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "85", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "April 19, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01841775", 
            "org_study_id": "VIGAT-RJ IFN\u03b12b"
        }, 
        "intervention": {
            "description": "interferon \u03b1 2b: 3.000.000 IU SUBQ 3 times / wk for 24 weeks\nribavirin 250 mg: 15mg/kg/day,ORALLY twice a day for 24 weeks", 
            "intervention_name": "interferon \u03b1 2b + ribavirin", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Interferons", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Hepatitis C, Chronic", 
            "Genotype 2/3", 
            "Interferon \u03b1 2b", 
            "Ribavirin", 
            "Pharmacovigilance"
        ], 
        "lastchanged_date": "April 24, 2013", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Rio de Janeiro", 
                        "country": "Brazil", 
                        "state": "RJ", 
                        "zip": "21941-913"
                    }, 
                    "name": "Hospital Universit\u00e1rio Clementino Fraga Filho (Clementino Fraga Filho University Hospital)"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Rio de Janeiro", 
                        "country": "Brazil", 
                        "zip": "21041-030"
                    }, 
                    "name": "Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital)"
                }
            }
        ], 
        "location_countries": {
            "country": "Brazil"
        }, 
        "number_of_arms": "1", 
        "official_title": "Pharmacovigilance Study of the Interferon \u03b1 2b Produced by Bio-Manguinhos / Fiocruz and Used by Genotype 2/3 Chronic Hepatitis C Patients (Estudo de farmacovigil\u00e2ncia da Alfainterferona 2b Humana Recombinante Produzida Por Bio-Manguinhos - Fiocruz, Utilizada em Portadores de Hepatite C cr\u00f4nica gen\u00f3tipos 2 e 3 Atendidos Pelo Programa de Medicamentos de Dispensa\u00e7\u00e3o em Car\u00e1ter Excepcional no Estado do Rio de Janeiro)", 
        "overall_official": [
            {
                "affiliation": "The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)", 
                "last_name": "Eliane M. dos Santos, MD, MSc", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)", 
                "last_name": "Paulo Roberto G. dos Santos, PharmD, MSc", 
                "role": "Study Director"
            }, 
            {
                "affiliation": "The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)", 
                "last_name": "Deborah A. da Concei\u00e7\u00e3o, BScN", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Brazil: National Health Surveillance Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "September 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Diary for recording adverse events by patients daily;\nMonthly follow-up interview with MD and PharmD", 
            "measure": "Adverse events", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01841775"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Sustained virological response", 
            "safety_issue": "No", 
            "time_frame": "24 weeks after finishing treatment"
        }, 
        "source": "The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Hospital Federal de Bonsucesso (Bonsucesso Federal Hospital)", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Hospital Universit\u00e1rio Clementino Fraga Filho (Clementino Fraga Filho University Hospital)", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "The Immunobiological Technology Institute (Bio-Manguinhos) / Oswaldo Cruz Foundation (Fiocruz)", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "May 2009", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}